Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study.
Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A; QUASAR Study Group. Peyrin-Biroulet L, et al. Gastroenterology. 2023 Dec;165(6):1443-1457. doi: 10.1053/j.gastro.2023.08.038. Epub 2023 Sep 1. Gastroenterology. 2023. PMID: 37659673 Free article. Clinical Trial.
Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Hoffstadt M, Krause T, Schweitzer A, Schnoy E, Atreya R, Teich N, Trentmann L, Ehehalt R, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: mohl w. Inflamm Bowel Dis. 2024 May 2;30(5):746-756. doi: 10.1093/ibd/izad138. Inflamm Bowel Dis. 2024. PMID: 37523666
Real-world effectiveness of vedolizumab compared to anti-TNF agents in biologic-naïve patients with ulcerative colitis: A two-year propensity-score-adjusted analysis from the prospective, observational VEDOIBD -study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Efken P, Mohl W, Krause T, Hoffstadt M, Ehehalt R, Trentmann L, Schweitzer A, Jessen P, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: mohl w. Aliment Pharmacol Ther. 2023 Aug;58(4):429-442. doi: 10.1111/apt.17616. Epub 2023 Jun 15. Aliment Pharmacol Ther. 2023. PMID: 37322825
Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
Bokemeyer B, Plachta-Danielzik S, di Giuseppe R, Mohl W, Teich N, Hoffstadt M, Schweitzer A, von der Ohe M, Gauss A, Atreya R, Krause T, Blumenstein I, Hartmann P, Schreiber S. Bokemeyer B, et al. Among authors: mohl w. Inflamm Bowel Dis. 2023 Nov 2;29(11):1741-1750. doi: 10.1093/ibd/izac271. Inflamm Bowel Dis. 2023. PMID: 36633301
[Effects of SARS-CoV-2 Infection on Symptoms and Therapy of Inflammatory Bowel Disease].
Teich N, Ludewig C, Schmelz R, Bästlein EC, Geißler S, Nagl S, Walldorf J, Krause T, Maaser C, Mohl W, Wedemeyer HH, Bauer T, Büning C, Grunert P, Hasselblatt P, Hänschen M, Kahl M, Engelke O, Schubert S, Holler B, Streetz K, Arnim UV, Schmidt K, Stallmach A; für die German IBD Study Group; Collaborators:; Jochen Maul, Berlin; Axel Schweitzer, Münster; Wolfgang Breit, Dinkelsbühl; Jan-Hinnerk Hofer, Köln; Marc Eisold, Mössingen; Michael R. Mroß, Berlin; Stefanie Howaldt, Hamburg; Stefanie Strobl, Ingolstadt; Robert Ehehalt, Heidelberg; Klaus Schmidt, Lübeck; Carsten Triller, Heinsberg; Serhat Aymaz, Düren; Thorsten Brechmann, Bochum; Axel Dignaß, Frankfurt; Elisabeth Schnoy, Augsburg; Bernd Swarovsky, Albstadt; Dr. med. Birgit Gerhard, Berlin; Doris Zink, Nürnberg; Ulrich Finger, Berlin; Franz Josef Heil, Andernach; Gerd-Rüdiger Franke, Dinkelsbühl; Günther Böhm, Ludwigshafen; Jens Hunkemöller, Oberberg; Martin Schmidt-Lauber, Oldenburg; Mirko Vonderach, Oldenburg; Olaf Mensler, Oberberg; Rainer Kunz, Fürstenfeldbruck; Richard Kölble, Düsseldorf; Christoph Rother, Sundern; Ulf Klönne, Göttingen; Ulrich Graefe, Berlin; Wolfgang Schwarz, Hamburg; Georg Schmitz, Düren; Hans Vi… See abstract for full author list ➔ Teich N, et al. Among authors: mohl w. Z Gastroenterol. 2021 Nov;59(11):1189-1196. doi: 10.1055/a-1508-6734. Epub 2021 Jul 16. Z Gastroenterol. 2021. PMID: 34748206 German.
[Position paper on endoscopic reporting in IBD].
Schmidt C, Bachmann O, Baumgart DC, Goetz M, Drvarov O, Kucharzik TF, Kühbacher T, Langhorst J, Maul J, Mohl W, Mudter J, Repp M, Sturm A, Witzemann D, Atreya R. Schmidt C, et al. Among authors: mohl w. Z Gastroenterol. 2021 Oct;59(10):1091-1109. doi: 10.1055/a-1504-9782. Epub 2021 Jul 20. Z Gastroenterol. 2021. PMID: 34284522 German.
Profile of patients with inflammatory bowel disease in conjunction with unmet needs and decision-making for choosing a new biologic therapy: a baseline analysis of the VEDOIBD-Study.
di Giuseppe R, Plachta-Danielzik S, Mohl W, Hoffstadt M, Krause T, Bokemeyer B, Schreiber S. di Giuseppe R, et al. Among authors: mohl w. Int J Colorectal Dis. 2021 Nov;36(11):2445-2453. doi: 10.1007/s00384-021-03943-5. Epub 2021 May 8. Int J Colorectal Dis. 2021. PMID: 33963913
115 results